• 11-AUG-2014

  • SOURCE: Novo Nordisk A/S

<i>Diabetes Care</i> to publish data on safety and efficacy of IDegLira from the DUAL™ programme

Novo Nordisk Logo
For the first time, data on the safety and efficacy of IDegLira from the DUAL™ programme will be published in a peer-review journal (Diabetes Care). IDeglira is the once-daily combination of Tresiba® (insulin degludec) and Victoza® (liraglutide) in one pen for people with type 2 diabetes.

A press release, images and a clinical trial backgrounder will be distributed through http://www.thenewsmarket.com today at 16:00 pm CEST.

Contact

  • Client Relations
    TheNewsMarket